NMN

NMN is built from nicotinamide and ribose and sits one step upstream of NAD+ in the salvage pathway, the route cells use to recycle NAD+ from vitamin B3 ^[4]. NAD+ is a central coenzyme that carries electrons in metabolism and serves as a substrate for enzymes such as sirtuins and PARPs involved in DNA repair and signaling, so its availability is tied to cellular energy and maintenance ^[4]. NMN occurs naturally in small amounts in foods such as edamame, broccoli, and avocado, though at concentrations far below supplement doses ^[3].

Much of the enthusiasm for NMN comes from rodent studies. In one experiment, twelve months of oral NMN in normally aging mice was quickly converted to NAD+ in tissues and mitigated several age-associated changes, including weight gain, declining energy metabolism, reduced physical activity, and worsening insulin sensitivity, without evident toxicity ^[3]. Human data are more limited. A randomized, placebo-controlled trial in postmenopausal women with prediabetes found that NMN improved skeletal-muscle insulin sensitivity and insulin signaling ^[1], and a separate clinical study reported that single oral doses were safe and raised circulating nicotinamide metabolites in healthy men ^[2]. Reviewers emphasize that no human study has yet demonstrated the broad anti-aging benefits inferred from animal work ^[3].

NMN is sold mainly as an oral capsule or powder. How it enters cells has been debated; a proposed dedicated transporter would allow direct uptake, while others argue that NMN is first converted to nicotinamide riboside before absorption, and the question is not fully resolved ^[1][4]. Regardless of route, oral NMN reliably raises blood NAD+ metabolites in people ^[2]. Its status as a supplement was contested in the United States: FDA objected in 2022 on the grounds that NMN had been authorized for investigation as a new drug, then reversed that interpretation on September 29, 2025 and concluded that NMN is not excluded from the dietary supplement definition.

Oral NMN has been well tolerated in every randomized trial published so far, and that now rests on pooled data rather than single studies. Two meta-analyses, covering twelve and fifteen trials, found no increase in overall adverse events, serious adverse events, withdrawals, or ALT and AST against placebo, across doses from 250 to 2000 mg per day ^[7][6]. A dedicated safety trial gave 1250 mg once daily for four weeks to 31 healthy adults with no severe adverse events ^[22].

The honest limit is duration. The longest published randomized oral NMN exposures are two 24-week trials in older Japanese men with diabetes, fourteen participants each ^[23][24], and the 2026 pooled review describes the durations of its own fifteen included trials as 14 days to 24 weeks ^[6]. Nothing in the human record speaks to years of continuous use, which is exactly how the product is sold.

Two open questions deserve naming rather than silence. NAD+ is a substrate that dividing cells need, and NAD+ metabolism is entangled with tumour metabolism, so whether sustained precursor dosing is neutral in someone with an occult cancer has not been tested in people; the concern is mechanistic and unresolved, not an observed harm ^[28][29]. And CD38, the main enzyme degrading NMN in vivo, is an immune-cell ectoenzyme ^[15], which is a reason to study the immune consequences of chronic NAD+ loading rather than assume them.

United States regulatory status changed, and in NMN's favour. FDA ruled NMN out of the dietary supplement definition in October and November 2022 on drug-preclusion grounds, then reversed that reading on September 29, 2025 and set the 2022 letters aside on December 2, 2025.

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme central to cellular energy metabolism. NMN itself has been recognized biochemically for many decades as an intermediate in the NAD+ salvage pathway, but scientific and commercial interest in it as a supplement is comparatively recent.

That interest was driven largely by research in the 2000s and 2010s, notably work from the laboratory of Shin-ichiro Imai at Washington University and collaborators, which demonstrated that oral NMN could raise NAD+ levels and improve various metabolic and physiological measures in aged mice. These findings, situated within the broader field of NAD+ biology and aging, spurred a wave of preclinical studies and the emergence of NMN as a popular longevity-oriented supplement, followed by early human clinical trials assessing its bioavailability, safety, and effects.

NMN is one of the most prominent supplements in the contemporary longevity movement and is regarded with a mixture of enthusiasm and caution. Proponents, including some well-known aging researchers, view it as a promising means of restoring declining NAD+ levels and supporting metabolic health, energy, and healthy aging, and early human trials have shown that oral dosing can raise blood NAD+ concentrations and appears well tolerated.

At the same time, the scientific community stresses that the strongest evidence remains in animal models, that human trials are still relatively few, short, and focused on surrogate markers rather than hard clinical outcomes, and that claims of anti-aging or lifespan benefits in people remain unproven. Its regulatory status has also been contested in some markets. Overall it is seen as a scientifically interesting and generally safe supplement whose real-world benefits are still being established.